title: Antipsychotics and hyperprolactinaemia: clinical recommendations.
abstract: A group of international experts in psychiatry, medicine, toxicology and pharmacy assembled to undertake a critical examination of the currently available clinical guidance on hyperprolactinaemia. This paper summarises the group's collective views and provides a summary of the recommendations agreed by the consensus group to assist clinicians in the recognition, clinical assessment, investigation and management of elevated plasma prolactin levels in patients being treated for severe mental illness. It also deals with the special problems of particular populations, gives advice about information that should be provided to patients, and suggests a strategy for routine monitoring of prolactin. The recommendations are based upon the evidence contained in the supplement 'Hyperprolactinaemia in schizophrenia and bipolar disorder: Clinical Implications' (2008). The guidance contained in this article is not intended to replace national guidance (such as that of the National Institute of Clinical Excellence), however, it does provide additional detail that is unlikely to be covered in existing guidelines, and focuses on areas of uncertainty and disagreement. We hope it will add to the debate about this topic.
authors.affiliation: University of Southampton, Royal South Hants Hospital, Southampton, UK. rcp@soton.ac.uk
authors.forename: Robert C
authors.initials: RC
authors.lastname: Peveler
authors.forename: David
authors.initials: D
authors.lastname: Branford
authors.forename: Leslie
authors.initials: L
authors.lastname: Citrome
authors.forename: Peter
authors.initials: P
authors.lastname: Fitzgerald
authors.forename: Philip W
authors.initials: PW
authors.lastname: Harvey
authors.forename: Richard I G
authors.initials: RI
authors.lastname: Holt
authors.forename: Louise
authors.initials: L
authors.lastname: Howard
authors.forename: Dora
authors.initials: D
authors.lastname: Kohen
authors.forename: Ian
authors.initials: I
authors.lastname: Jones
authors.forename: Veronica
authors.initials: V
authors.lastname: O'Keane
authors.forename: Carmine M
authors.initials: CM
authors.lastname: Pariente
authors.forename: John
authors.initials: J
authors.lastname: Pendlebury
authors.forename: Shubulade M
authors.initials: SM
authors.lastname: Smith
authors.forename: David
authors.initials: D
authors.lastname: Yeomans
mesh_terms: D014150:Antipsychotic Agents / Q000009:adverse effects*; D035843:Biomedical Research; D015519:Bone Density / Q000187:drug effects; D016903:Drug Monitoring; D007722:Health Knowledge, Attitudes, Practice; D006801:Humans; D006966:Hyperprolactinemia / Q000139:chemically induced* / Q000150:complications / Q000378:metabolism / Q000628:therapy; D001523:Mental Disorders / Q000188:drug therapy* / Q000378:metabolism; D010353:Patient Education as Topic; D017410:Practice Guidelines as Topic; D011388:Prolactin / Q000097:blood / Q000378:metabolism*; D009626:Terminology as Topic
chemical_list: D014150:Antipsychotic Agents; D011388:Prolactin